Similar Papers

Paper Title
Journal
Date
Author
Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)
Florian Guisier ... Chantal Decroisette
Clinical Lung Cancer | VOL. 23
Florian Guisier, et. al.Florian Guisier ... Chantal Decroisette
17 Sep 2022
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
Caicun Zhou ...
The Lancet Oncology | VOL. 23
Caicun Zhou, et. al.Caicun Zhou ...
01 Feb 2022
Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.
Wenjie Liu ... Peng Chen
Frontiers in Immunology | VOL. 13
Wenjie Liu, et. al.Wenjie Liu ... Peng Chen
21 Jun 2022
Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.
Keunchil Park ... Ki Hyeong Lee
Journal of Clinical Oncology | VOL. 35
Keunchil Park, et. al.Keunchil Park ... Ki Hyeong Lee
01 Mar 2017
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Rethinking the Path to Bladder Cancer Staging: Can Magnetic Resonance Imaging Speed Up Time to Receipt of Therapy in Patients With Muscle-Invasive Bladder Cancer?
Ashish M Kamat ... Paul Frankel
Journal of Clinical Oncology | VOL. -
Ashish M Kamat, et. al.Ashish M Kamat ... Paul Frankel
05 Feb 2025
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials
Julien Taieb ... Pierre Laurent-Puig
Journal of Clinical Oncology | VOL. -
Julien Taieb, et. al.Julien Taieb ... Pierre Laurent-Puig
04 Feb 2025
Aiming Targeted Drug Development at Rare Pediatric Malignancies
Julia L Glade Bender
Journal of Clinical Oncology | VOL. -
Julia L Glade BenderJulia L Glade Bender
03 Feb 2025
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859.
Sun Young Rha ... Do-Youn Oh
Journal of Clinical Oncology | VOL. 43
Sun Young Rha, et. al.Sun Young Rha ... Do-Youn Oh
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.